MASLD与MASH中的整合代谢:病理生理学与新兴机制
本文综述肠道-脂肪组织-肝脏轴的代谢通量,重点讨论从头脂肪生成、葡萄糖和果糖等膳食底物及线粒体功能改变在MASLD进展中的作用,并强调白色脂肪组织胰岛素抵抗和线粒体动力学受损对肝脏脂质积累的贡献。进一步理解胃肠道底物通量与脂肪组织及肝线粒体结构功能改变的交互,对识别新治疗靶点、推进MASLD和MASH治疗具有重要意义。
要点
- 肝脏整合胃肠道与脂肪组织信号,调控碳水化合物、脂质和氨基酸代谢。
- 肠道来源代谢物(乙酸盐、乙醇)和白色脂肪组织非酯化脂肪酸影响依赖线粒体功能的肝脏过程。
- 肥胖、胰岛素抵抗和2型糖尿病所致代谢失调破坏上述通路,导致MASLD和MASH。
核心结论
- 进一步理解胃肠道底物通量与脂肪组织整合、并与肝线粒体结构和功能改变相交汇的机制,对识别新治疗靶点和推进MASLD与MASH治疗具有重要意义。
研究设计与样本
- 综述,探讨肠道-脂肪组织-肝脏轴内的代谢通量。
主要发现
- 肠道来源代谢物如乙酸盐和乙醇、以及白色脂肪组织来源的非酯化脂肪酸影响肝脏过程,这些过程依赖线粒体功能维持全身能量平衡。
- 肥胖、胰岛素抵抗和2型糖尿病引起的代谢失调破坏上述通路,导致MASLD和MASH。
- 从头脂肪生成、葡萄糖和果糖等膳食底物以及MASLD进展中线粒体功能改变发挥关键作用。
- 白色脂肪组织胰岛素抵抗和线粒体动力学受损促进肝脏脂质积累。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The liver acts as a central metabolic hub, integrating signals from the gastrointestinal tract and adipose tissue to regulate carbohydrate, lipid, and amino acid metabolism. Gut-derived metabolites, such as acetate and ethanol, and non-esterified fatty acids from white adipose tissue influence hepatic processes, which rely on mitochondrial function to maintain systemic energy balance. Metabolic dysregulation caused by obesity, insulin resistance, and type 2 diabetes disrupts these pathways, leading to metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). In this review, we explore the metabolic fluxes within the gut-adipose tissue-liver axis, focusing on the pivotal role of de novo lipogenesis, dietary substrates like glucose and fructose, and changes in mitochondrial function during MASLD progression. We also highlight the contributions of white adipose tissue insulin resistance and impaired mitochondrial dynamics to hepatic lipid accumulation. Further understanding how the interplay between substrate flux from the gastro-intestinal tract integrates with adipose tissue and intersects with structural and functional alterations to liver mitochondria will be important to identify novel therapeutic targets and advance the treatment of MASLD and MASH.
引用
- Steinberg GR, Valvano CM, De Nardo W, et al. Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms. J Hepatol. 2025. PMID: 40032040. doi:10.1016/j.jhep.2025.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。